|
| CDK4/6 inhibition alone and in combination for nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.26545
Jose Pacheco, and Erin Schenk
|
| 618-619 |
|
| DNA polymerases as chemotherapy targets: promise and challenges |
|
https://doi.org/10.18632/oncotarget.26572
Kristin A. Eckert, and Ryan P. Barnes
|
| 620-621 |
|
| Role of transcriptionregulating kinase CDK8 in colon cancer metastasis |
|
https://doi.org/10.18632/oncotarget.26593
Jiaxin Liang, Mengqian Chen, Eugenia V. Broude, and Igor B. Roninson
|
| 622-623 |
|
| Concurrent chemotherapy in oropharyngeal cancer: Cisplatin wins |
|
https://doi.org/10.18632/oncotarget.26594
Arya Amini, and Sana D. Karam
|
| 624-625 |
|
| The dawn of a new era in treating TPLL |
|
https://doi.org/10.18632/oncotarget.26595
Alexandra Schrader, Till Braun, and Marco Herling
|
| 626-628 |
|
| AEG1 targeting for inhibiting inflammation: potential antiHCC strategy |
|
https://doi.org/10.18632/oncotarget.26602
Saranya Chidambaranathan Reghupaty, Rachel Mendoza, and Devanand Sarkar
|
| 629-630 |
|
| Modeling the prevalent germline TP53 R337H mutation in mouse |
|
https://doi.org/10.18632/oncotarget.26603
Ji-Hoon Park, Ping-Yuan Wang, and Paul M. Hwang
|
| 631-632 |
|
| Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma |
|
https://doi.org/10.18632/oncotarget.26551
Yutaka Takahashi, Tomohiro Yasui, Kazumasa Minami, Keisuke Tamari, Kazuhiko Hayashi, Keisuke Otani, Yuji Seo, Fumiaki Isohashi, Masahiko Koizumi, and Kazuhiko Ogawa
|
| 633-646 |
|
| SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition |
|
https://doi.org/10.18632/oncotarget.26567
Esteban A. Terzo, Aaron R. Lim, Anna Chytil, Yun Chen Chiang, Leah Farmer, Kathryn H. Gessner, Cheryl Lyn Walker, Valerie M. Jansen, and W. Kimryn Rathmell
|
| 647-659 |
|
| Preoperative MRIradiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone |
|
https://doi.org/10.18632/oncotarget.26578
Florent Tixier, Hyemin Um, Dalton Bermudez, Aditi Iyer, Aditya Apte, Maya S. Graham, Kathryn S. Nevel, Joseph O. Deasy, Robert J. Young, and Harini Veeraraghavan
|
| 660-672 |
|
| Downregulation of miR1945p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression |
|
https://doi.org/10.18632/oncotarget.26586
Koji Nakamura, Kenjiro Sawada, Mayuko Miyamoto, Yasuto Kinose, Akihiko Yoshimura, Kyoso Ishida, Masaki Kobayashi, Aasa Shimizu, Erika Nakatsuka, Kae Hashimoto, Seiji Mabuchi, and Tadashi Kimura
|
| 673-683 |
|
| Correction: Upregulation of p16 by miR8773p inhibits proliferation of bladder cancer |
|
https://doi.org/10.18632/oncotarget.26624
Shiqi Li, Yi Zhu, Zhen Liang, Xiao Wang, Shuai Meng, Xin Xu, Xianglai Xu, Jian Wu, Alin Ji, Zhenghui Hu, Yiwei Lin, Hong Chen, Yeqing Mao, Wei Wang, Xiangyi Zheng, Ben Liu, and Liping Xie
|
| 684-684 |
|
| Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer |
|
https://doi.org/10.18632/oncotarget.26625
Jonathan P. Evans, Boleslaw K. Winiarski, Paul A. Sutton, Robert P. Jones, Lorenzo Ressel, Carrie A. Duckworth, D. Mark Pritchard, Zhi-Xiu Lin, Vicky L. Fretwell, Elizabeth M. Tweedle, Eithne Costello, Christopher E. Goldring, Ian M. Copple, B. Kevin Park, Daniel H. Palmer, and Neil R. Kitteringham
|
| 685-685 |
